EyePoint Pharmaceuticals, Inc.
EYPT
$4.13
-$0.49-10.61%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 11.59M | 10.52M | 9.48M | 11.68M | 14.03M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.59M | 10.52M | 9.48M | 11.68M | 14.03M |
| Cost of Revenue | -68.49M | 29.31M | 5.01M | 30.90M | -40.19M |
| Gross Profit | 80.08M | -18.79M | 4.47M | -19.21M | 54.22M |
| SG&A Expenses | 13.60M | 13.96M | 13.32M | 14.11M | 11.72M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 56.83M | 43.27M | 44.02M | 45.01M | 30.38M |
| Operating Income | -45.24M | -32.75M | -34.55M | -33.32M | -16.35M |
| Income Before Tax | -41.31M | -29.36M | -30.83M | -29.28M | -14.02M |
| Income Tax Expenses | 90.00K | -- | -- | -- | 83.00K |
| Earnings from Continuing Operations | -41.40M | -29.36M | -30.83M | -29.28M | -14.10M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -41.40M | -29.36M | -30.83M | -29.28M | -14.10M |
| EBIT | -45.24M | -32.75M | -34.55M | -33.32M | -16.35M |
| EBITDA | -44.77M | -32.34M | -34.18M | -33.02M | -16.24M |
| EPS Basic | -0.64 | -0.54 | -0.58 | -0.55 | -0.33 |
| Normalized Basic EPS | -0.40 | -0.34 | -0.36 | -0.35 | -0.21 |
| EPS Diluted | -0.64 | -0.54 | -0.58 | -0.55 | -0.33 |
| Normalized Diluted EPS | -0.40 | -0.34 | -0.36 | -0.35 | -0.21 |
| Average Basic Shares Outstanding | 64.56M | 54.45M | 53.21M | 52.91M | 42.17M |
| Average Diluted Shares Outstanding | 64.56M | 54.45M | 53.21M | 52.91M | 42.17M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
